enGene Inc. Common Stock (ENGN)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
The company was founded in 2023 and is based in Saint-Laurent, Canada.
Country | CA |
IPO Date | Feb 1, 2022 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 31 |
CEO | Ronald H. W. Cooper |
Contact Details
Address: 7171 Rue Frederick Banting Saint-Laurent, CA | |
Website | https://www.engene.com |
Stock Details
Ticker Symbol | ENGN |
Exchange | NASDAQ |
Fiscal Year | November - October |
Reporting Currency | USD |
CIK Code | 0001100663 |
CUSIP Number | n/a |
ISIN Number | CA29286M1059 |
Employer ID | 94-3351276 |
SIC Code |
Key Executives
Name | Position |
---|---|
Ronald H. W. Cooper | Chief Executive Officer & Director |
David Ryan Daws | Chief Financial Officer & Head of Business Development |
Joan Connolly | Chief Technology Officer |
Lee G. Giguere | Chief Legal Officer & Corporate Secretary |
Dr. Alex Nichols Ph.D. | Chief Strategy & Operations Officer |
Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
Dr. Raj Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer |
John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
Paul Erickson | Non-Executive Director |
Sharon Tan | Vice President of Project Management & Head of Program Management |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |
Jan 24, 2025 | NPORT-P | Filing |